Drug shows positive responses, low side-effects in multiple myeloma
(University of Texas M. D. Anderson Cancer Center) The second-generation proteasome inhibitor carfilzomib is showing noteworthy response rates and low levels of adverse side effects among multiple myeloma patients in a phase II clinical trial, researchers report.
source : www.eurekalert.org
How DUMB are YOU?!
Do your friends think you are stupid? Take the challenge and prove them wrong!
Gevalia Stainless Steel Bundle
Save 75% on this Coffee Bundle When You Try Gevalia!
Get 5 Books for 99 cents!
The most popular books at the most popular prices!
Home Income Profit System
You can make money working from the comfort of your own home!
Take the IQ Challenge!
Are you as stupid as your friends think? Prove them wrong with this quick IQ Challenge game!
Do your friends think you are stupid? Take the challenge and prove them wrong!
Gevalia Stainless Steel Bundle
Save 75% on this Coffee Bundle When You Try Gevalia!
Get 5 Books for 99 cents!
The most popular books at the most popular prices!
Home Income Profit System
You can make money working from the comfort of your own home!
Take the IQ Challenge!
Are you as stupid as your friends think? Prove them wrong with this quick IQ Challenge game!
Related News:
- Acne Drug Prevents HIV Breakout
- Increasing Understanding Of Drug Metabolism Provides Key Knowledge About Drug Toxicity And Effectiveness
- SGO: Drug Combination Slows Recurrent Ovarian Cancer
- PEGylated dendrimers: A novel mechanism of drug delivery
- New Drug Candidate Reduces Blood Lipids
- Agency For Healthcare Research And Quality News And Numbers: High Cholesterol, Diabetes Lead Drug Spending For The Elderly
- Grandfathered Drug For High Potassium Has No Proven Benefit
- Medicare to Drug Plan Operator: You’re Fired
- Hot road to new drugs: Efficient identification of drug candidates
- Advanced Cell Technology’s RPE Cells Granted Orphan Drug Status From FDA For Treatment Of Stargardt’s Macular Dystrophy
Details :
Submited at Monday, December 7th, 2009 at 1:00 pm on Cancer and Oncology by sofia
Comment RSS 2.0 - leave a comment - trackback
Leave Comment Here...